[4-methoxy-3-(morpholin-4-ylsulphonyl)phenyl]boronic acid | 871333-02-7

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-methoxy-3-(morpholin-4-ylsulphonyl)phenyl]boronic acid
• 英文别名: 4-methoxy-3-(morpholinosulfonyl)phenylboronic acid；(4-Methoxy-3-(morpholinosulfonyl)phenyl)boronic acid；(4-methoxy-3-morpholin-4-ylsulfonylphenyl)boronic acid
• CAS: 871333-02-7
• 化学式: C₁₁H₁₆BNO₆S
• 分子量: 301.128
• InChiKey: MCYOYCLLZQYKDW-UHFFFAOYSA-N

物化性质

• 熔点：
  270-276
• 沸点：
  562.8±60.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2935009090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Methoxy-3-(N-morpholinylsulfonyl)phenylboronic acid
Product Name:
Synonyms: (4-Boronoanisole-2-sulfonyl)morpholine; 4-(5-borono-2-methoxybenzenesulfonyl)morpholine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Methoxy-3-(N-morpholinylsulfonyl)phenylboronic acid
Ingredient name:
CAS number: 871333-02-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H16BNO6S
Molecular weight: 301.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N³-(4-bromo-3-chloro-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazole-3,5-diamine 、 [4-methoxy-3-(morpholin-4-ylsulphonyl)phenyl]boronic acid 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 乙二醇二甲醚 为溶剂， 反应 3.0h， 以16%的产率得到N3-(2-chloro-4'-methoxy-3'-(morpholinosulfonyl)-6-(trifluoromethyl)biphenyl-4-yl)-1H-1,2,4-triazole-3,5-diamine
  参考文献：
  名称：

  [EN] ANTIVIRAL COMPOUNDS
  [FR] COMPOSÉS ANTIVIRAUX

  摘要：

  本发明公开了化合物的结构式I：其中结构式I中的变量如本文所述。还公开了含有这些化合物的药物组合物，以及使用结构式I中的化合物预防或治疗HCV感染的方法。

  公开号：

  WO2014135495A1

文献信息

• SUBSTITUTED PHENYLALANINE DERIVATIVES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160244437A1

  公开（公告）日：2016-08-25

  The invention relates to substituted phenylalanine derivatives and to processes for preparation thereof, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and/or severe perioperative blood loss.

  本发明涉及取代苯丙氨酸衍生物及其制备方法，以及将其用于生产用于治疗和/或预防疾病的药物，特别是心血管疾病和/或严重围手术期失血的药物。
• Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC 50 for a proof-of-principle study
  作者：Ahmed S. Abdelsamie、Chris J. van Koppen、Emmanuel Bey、Mohamed Salah、Carsten Börger、Lorenz Siebenbürger、Matthias W. Laschke、Michael D. Menger、Martin Frotscher

  DOI：10.1016/j.ejmech.2016.11.004

  日期：2017.2

  discovery of (5-(3,5-dichloro-4-methoxyphenyl)thiophen-2-yl)(2,6-difluoro-3-hydroxyphenyl)methanone 20, which displayed a sub-nanomolar IC50 towards 17β-HSD1 as well as high selectivity over the type 2 enzyme, the estrogen receptors α and β and a range of hepatic CYP enzymes. The compound did neither show cellular toxicity, nor PXR activation nor mutagenicity in the AMES II assay. Additional favourable pharmacokinetic

  当前用于雌激素依赖性疾病子宫内膜异位症的内分泌治疗剂通常会引起相当大的副作用，因为它们通过全身性地降低雌激素作用而起作用。最近的方法利用了以下事实：血浆中富含的雌激素雌激素（E1）在靶细胞中被17β-羟类固醇脱氢酶1型（17β-HSD1）激活为高雌激素雌二醇（E2）。 。17β-HSD1在子宫内膜异位症中过表达，因此是治疗该疾病的有希望的靶标，并有望减少与靶标相关的副作用。我们最近描述的具有磺酰胺部分的双环取代的羟基苯基亚甲酮类的强抑制剂在17β-HSD1的生理对手——17βHSD2上具有高分子量和低选择性。我们描述了导致（5-（3,5-二氯-4-甲氧基苯基）噻吩-2-基）（2,6-二氟-3-羟苯基）甲酮20的发现的结构优化，它显示了亚纳摩尔级对17β-HSD1的IC50以及对2型酶，雌激素受体α和β以及一系列肝CYP酶的高选择性。该化合物在AMES II分析中既未显示出细胞毒性，也未显示
• ANTIVIRAL COMPOUNDS
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20160000760A1

  公开（公告）日：2016-01-07

  The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

  本发明公开了I式化合物：其中I式中的变量如本文所述。还公开了包含这种化合物的药物组合物，以及使用I式化合物在预防或治疗HCV感染方面的方法。
• Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents
  作者：P. Muthuraja、V. Veeramani、S. Prakash、M. Himesh、U. Venkatasubramanian、P. Manisankar

  DOI：10.1016/j.bioorg.2018.12.014

  日期：2019.3

  Human kinesin Eg5 is a potential inhibiting site for cancer chemotherapy. Blocking metaphase by binding foreign inhibitors with Eg5 eventually leads to apoptotic cell death. Here, we report the pyrazolopyrimidine derivates as potent inhibitors of Eg5 that prevents mitotic kinesin progression. IC50 values were evaluated against the motor domain of Eg5 using steady-state ATPase assay. To better understanding, we have performed molecular docking simulation. It reveals that the interactions of the proposed inhibitors with both the allosteric sites (helices alpha 2, alpha 3 and loopL5, and helices alpha 4 & alpha 6). Out of fifteen pyrazolopyrimidine derivates, three compounds (12, 25, and 27) have shown significant inhibition of Eg5. The synthesized compounds (12, 25, and 27) were tested for their in-vitro anticancer activity against cervical cancer cell line (HeLa).
• Sulfonyl-Containing Boronate Caps for Optimization of Biological Properties of ^99mTc(III) Radiotracers [^99mTcCl(CDO)(CDOH)₂B-R] (CDOH₂ = Cyclohexanedione Dioxime)
  作者：Zuo-Quan Zhao、Min Liu、Wei Fang、Shuang Liu

  DOI：10.1021/acs.jmedchem.7b01412

  日期：2018.1.11

  In this study, different boronate caps were used to optimize biodistribution properties of radiotracers [(TcCl)-Tc-99m(CDO)(CDOH)(2)B-R] (1, R = 3S; 2, R = 3SP; 3, R = 3MS; 4, R = 3DMS; 5, R = 3MSB; 6, R = 3MMS; 7, R = 3MSA; 8, R = 3DMSA; 9, R = 4S; 10, R = 4MS; 11, R = 4MSB). Among the 11 new Tc-99m radiotracers, 2 shows the most promising characteristics of an optimal heart imaging agent. Its initial heart uptake is close to that of Tc-99m-Teboroxime, but its heart retention time is significantly longer. Its heart/liver, heart/lung, and heart/muscle ratios are also better than those of Tc-99m-Teboroxime. The SPECT image quality with 2 in SD rats is better than that with Tc-99m-Teboroxime. The high initial heart uptake, long heart retention, and high heart/background ratios make 2 an excellent SPECT radiotracer for MPI.